RT Journal Article SR Electronic T1 SERPINB11 Expression Is Associated With Prognosis of High-grade Serous and Clear Cell Carcinoma of the Ovary JF In Vivo JO In Vivo FD International Institute of Anticancer Research SP 2647 OP 2653 DO 10.21873/invivo.12547 VO 35 IS 5 A1 SOO JIN PARK A1 WHASUN LIM A1 JAEHEE MUN A1 HAERIN PAIK A1 SUNWOO PARK A1 HYUNJI LIM A1 JUNHWAN KIM A1 EUN JI LEE A1 GA WON YIM A1 NARA LEE A1 CHEOL LEE A1 JAE-WEON KIM A1 GWONHWA SONG A1 HEE SEUNG KIM YR 2021 UL http://iv.iiarjournals.org/content/35/5/2647.abstract AB Background/Aim: To evaluate the role of serine protease inhibitor B11 (SERPINB11) expression as a prognostic biomarker in high-grade serous carcinoma (HGSC) and clear cell carcinoma of the ovary (CCC). Materials and Methods: We obtained tumor tissues from patients with HGSC (n=145) and CCC (n=59). We evaluated immunohistochemically the expression of SERPINB11 and investigated whether SERPINB11 expression affects platinum-resistance and the prognosis of HGSC and CCC. Results: High expression of SERPINB11 was more common in CCC than in HGSC (57.6% vs. 28.3%; p<0.01), and SEPRINB11 expression did not correlate with platinum-resistance of HGSC and CCC. High expression of SERPINB11 was associated with worse progression-free survival and overall survival with marginal significance in HGSC; no relation between SERPINB11 expression and the prognosis of CCC was found. Conclusion: SERPINB11 expression maybe a prognostic biomarker for HGSC.